
Semaglutide Reduces Stroke Risk in American Males: A Prospective Cohort Study
Reading Time: 2 minutes Introduction Stroke remains a leading cause of morbidity and mortality among American males, necessitating effective preventive strategies. Recent research has begun to explore the potential benefits of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist traditionally used in the management of type 2 diabetes, in reducing the risk of stroke. This article delves into a prospective cohort study that investigates semaglutide's role in stroke prevention among American males, highlighting its implications for clinical practice. Study Design and Methodology The prospective cohort study involved a diverse group of American males aged 40 to 75 years, with varying degrees of cardiovascular risk factors....